Photodynamic therapy in the canine prostate using motexafin lutetium.

Our purpose was to determine the feasibility of comprehensive treatment of the canine prostate with photodynamic therapy (PDT) using motexafin lutetium (Lu-Tex) and to evaluate the toxicity and tissue effects associated with this treatment. Twenty-five adult male beagles with normal prostate glands were given an i.v. injection of the second-generation photosensitizer Lu-Tex (2-6 mg/kg). An additional two dogs were used as controls and did not receive any photosensitizing drug. All 27 dogs underwent laparotomy to expose the prostate. Three hours postinjection, a total dose of 75-150 J/cm of 732 nm laser light was delivered interstitially and/or transurethrally to the prostate via cylindrical diffusing fibers. Dogs were euthanized between 2 days and 3 months after PDT. All subjects were monitored for clinical evidence of toxicity. Specimens were examined macroscopically and microscopically to characterize the tissue reaction and assess extent of tissue effect as a result of treatment. Interstitial and/or transurethral PDT were successfully delivered in all dogs with no perioperative complications. No clinical evidence of acute urinary obstruction or rectal bleeding was noted. At all dose levels, macroscopic and microscopic evaluation revealed a prostatic tissue reaction characterized initially (within 48 h) by inflammation and necrosis followed by fibrosis and glandular epithelial atrophy. Comprehensive treatment of the entire prostate could be achieved using the interstitial alone approach or combined transurethral and interstitial approach. The transurethral alone approach did not result in complete coverage of the prostate. Dogs receiving transurethral or combined interstitial and transurethral treatment developed erythema and urethral epithelial disruption at all dose levels. Those receiving combined treatment at the highest dose level (Lu-Tex 6 mg/kg, 150 J/cm light) developed urethral fistulae and peritonitis. Dogs treated with the interstitial alone approach were found to have the least amount of urethral damage. Comprehensive treatment of the canine prostate with Lu-Tex PDT is feasible using an interstitial alone or combined interstitial and transurethral approach. The interstitial alone technique results in the least amount of toxicity. The prostatic tissue reaction to treatment is characterized by initial inflammation and necrosis followed by fibrosis and glandular epithelial atrophy.

[1]  D. Ornstein,et al.  Evaluation and management of the man who has failed primary curative therapy for prostate cancer. , 1998, The Urologic clinics of North America.

[2]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus. , 1997, Gastrointestinal endoscopy clinics of North America.

[3]  A. D'Amico,et al.  Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Shi-Chung Chang,et al.  Interstitial and transurethral photodynamic therapy of the canine prostate using meso‐tetra‐(m‐hydroxyphenyl) chlorin , 1996, International journal of cancer.

[5]  F. Hetzel,et al.  Interstitial photodynamic therapy in the canine prostate. , 1997, British journal of urology.

[6]  M. A. Samphilipo,et al.  Multimodality Correlative Study of Canine Brain Tumors: Proton Magnetic Resonance Spectroscopy, Positron Emission Tomography, and Histology , 1994, Investigative radiology.

[7]  R. Keck,et al.  Transperineal photodynamic ablation of the canine prostate. , 1996, The Journal of urology.

[8]  C. Whitehurst,et al.  In vivo laser light distribution in human prostatic carcinoma. , 1994, The Journal of urology.

[9]  Shi-Chung Chang,et al.  Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5‐aminolevulinic acid‐induced protoporphyrin IX , 1997, The Prostate.

[10]  Darren L. Johnson Photodynamic Therapy for Barrett's Esophagus , 2000 .

[11]  R. Stock,et al.  Prostate brachytherapy: Improvements in prostate volume measurements and dose distribution using interactive ultrasound guided implantation and three-dimensional dosimetry , 1995 .

[12]  M. Marberger,et al.  Predictability and significance of multifocal prostate cancer in the radical prostatectomy specimen. , 1999, Techniques in urology.

[13]  J. Sessler,et al.  Lutetium Texaphyrin (PCI‐0123): A Near‐Infrared, Water‐Soluble Photosensitizer , 1996, Photochemistry and photobiology.

[14]  M. Biel Photodynamic therapy and the treatment of head and neck neoplasia , 1998, The Laryngoscope.

[15]  D. V. Ash,et al.  Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. , 1994, British Journal of Cancer.

[16]  B. Wilson,et al.  Changes in in vivo optical properties and light distributions in normal canine prostate during photodynamic therapy. , 1997, Radiation research.

[17]  D. Kessel,et al.  Localization and Efficacy Analysis of the Phototherapeutic Lutetium Texaphyrin (PCI‐0123) in the Murine EMT6 Sarcoma Model , 1997, Photochemistry and photobiology.

[18]  Q. Peng,et al.  Photodynamic Therapy , 1988, Methods in Molecular Biology.

[19]  J. H. Kinsey,et al.  Photodynamic therapy for early stage squamous cell carcinoma of the lung. , 1997, Mayo Clinic proceedings.